AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

AstraZeneca to invest  billion in the U.S. as pharma tariffs weigh


The office building of international biopharmaceutical company AstraZeneca.

Cfoto | Future Publishing | Getty Images

AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs.

The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the “cornerstone” of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill.

The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca’s largest single manufacturing investment in the world and will “leverage AI, automation and data analytics to optimize production,” the company said.

The latest funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, and create “tens of thousands of jobs,” AstraZeneca added.

CEO Pascal Soriot said the commitment underpins the firm’s “belief in America’s innovation in biopharmaceuticals” and would support its ambition to reach $80 billion in annual revenue by 2030, half of which is expected to come from the U.S.

AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The United States accounted for over 40% of the company’s annual revenues in 2024.

In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion U.S. investment. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.’s public markets.

AstraZeneca is the most valuable business listed on London’s FTSE 100. The company declined to comment on the Times report.

Pharma firms ramp up U.S. spending

AstraZeneca’s funding announcement follows similar moves by global pharmaceutical firms — including Novartis, Sanofi and Roche and U.S.-headquartered Eli Lilly and Johnson & Johnson — who have all vowed over recent months to ramp up their U.S. investment amid U.S. President Donald Trump’s demands to reshore domestic manufacturing.

The industry is awaiting further clarity on the Trump administration’s pharma tariffs, with the final outcome of a Section 232 investigation into the sector due at the end of this month. An effort to rebalance U.S. drug prices with those paid by other countries is also underway.

Trump earlier this month suggested that the industry could face levies of up to 200%, with a brief 12-18 month grace period to allow firms to relocate manufacturing stateside. However, many firms and analysts have dubbed the time frame as insufficient.

“Typically for most medicines it’s a three to four year horizon. We’re working very hard to accelerate that as fast as we can and demonstrate we’re making the investments we have planned,” Novartis CEO Vas Narasimhan said last week during an earnings call, adding that he hoped the administration would make allowances.



Source

Israel strikes Gaza in first major test of ceasefire
World

Israel strikes Gaza in first major test of ceasefire

Palestinians transport an injured man following what, according to medics, was an Israeli strike, at Al-Aqsa Martyrs Hospital, in Deir al-Balah, central Gaza Strip, on Oct. 19, 2025. Mahmoud Issa | Reuters Israel’s military said it struck multiple targets on Sunday in Gaza, using aircraft and artillery, after it said Hamas militants shot at Israeli […]

Read More
China wants to play the long game with the U.S. What that means for Chinese stocks
World

China wants to play the long game with the U.S. What that means for Chinese stocks

As U.S.-China tensions escalate and overall market volatility rises, investment strategists expect Chinese stocks will hold up as the country doubles down on tech development. “For now I think as long as people’s sentiment on [the] U.S. is slightly positive, sentiment on China will continue to be positive,” said Liqian Ren, leader of quantitative investment […]

Read More
Earnings playbook: Netflix and Tesla among the big companies slated to report
World

Earnings playbook: Netflix and Tesla among the big companies slated to report

The third-quarter earnings season has gotten off to a strong start. Investors will look to this week’s batch of companies reporting to keep the momentum going. More than 80 S & P 500 companies are due to release results this week. Among them are Netflix , General Motors and Tesla . Those results will come […]

Read More